Fierce Biotech

Radiopharma companies merge after one receives surprise FDA rejection

Updated: Electra says $350M IPO will help it become a commercial biotech

This Rare Gene Drastically Raises Lung Cancer Risk in People Who Never Smoked

Novo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotech

A biotech hedge fund births a new immunology company

Novartis’ TREM2 drug fails Phase 2 ALS trial

Psychedelics Stock, Up 190% This Year, Flies High Again

Experts urge FDA to set clear safety and access standards for psychedelic drugs

Is Moderna, Merck's mRNA cancer vaccine win the start of a 'personalized medicine revolution'?

Scientists boycott American Diabetes Association as fallout of June conference fracas escalates

Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successes

Boston Scientific says unlikely to meet 2026 sales, profit forecast after cyberattack

Bristol Myers' blood cancer cell therapy succeeds in mid-stage trial

Roivant’s $14M bet on Bayer’s inhaled hypertension med pays off with phase 2 win

Inhibrx claims first win for long-sought immunotherapy target

AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes

The Heart Drug Pelacarsen Fails, Shocking Novartis and Cardiologists

Psilocybin May Prevent Nerve Damage Caused by Chemotherapy, Study Finds

Is Ultragenyx Stock a Buy After GTX-102 Flop? Analysts Point to Commercial Pipeline

Teva autoimmune antibody notches ph. 2 win in celiac disease

Novartis inks $3.2B subcutaneous delivery deal with Alteogen

Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody

There’s a big change for this year’s flu shot: When should you be vaccinated?

Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused

Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies

Genentech doubles down on ADC-resistance via $1B DualityBio pact

With mRNA back in the spotlight, tRNA shows potential to treat genetic disease

China is a Threat to Biotech’s Massive Bull Run

Largest ever ‘map’ of autism may hold clues for new targeted therapies

Founded by Metsera backers, Sentivera emerges with $1.5B inflammatory disease deal

Vacant lab space, shrinking workforce put Mass. in ‘unique position’ for biotech bounceback

Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism

FDA pauses Regenxbio gene therapy trial again due to safety concerns

FDA Approves Alzheimer’s Blood Test Developed by Roche and Eli Lilly

The FDA has granted clearance to a new Alzheimer’s disease blood test developed by Roche and Eli Lilly.

FDA approves robot that can find your vein, insert a needle, and draw blood without human help

After Moderna stock surge of 177% on cancer drug breakthrough, here's what Wall Street thinks happens next

Human brain organoids record the passage of time over multiple years

Amylyx Stock Surges 55% After GLP-1 Blocker Hits All Trial Goals

Exclusive: Third death in China's popular but opaque trials revealed, this time in CAR-T

AstraZeneca suffers another setback as it halts volrustomig lung cancer trial

Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goal

Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugs

AI brings savings to clinical trials: study

Definium hits another phase 3 homerun with psychedelic ‘sea change’ for anxiety

Samsung’s Galaxy Buds are getting an FDA-approved hearing aid feature

Regeneron backs $75M series A for antibody upstart Infinimmune

Silence Therapeutics aims at Takeda with new data in rare blood cancer

MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial

This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 34% on Good News.

Why Vertex Pharma Popped, As A Key Rival Plummeted 90%

‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series E

First poo transplant to treat food allergy in people has ‘exciting’ results

Amgen drops ph. 1 obesity drug, upping pressure on MariTide

Novo Nordisk shares dive after heart medicine fails trial, dealing another blow to its pipeline

5 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

FDA Panel Votes In Favor of Replimune’s Melanoma Treatment

9 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues

9 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial

5 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.

GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard

GSK is implementing a $2.5 billion, three-year restructuring initiative to prioritize late-stage drug development and reorganize its research operations.

MapLight shares sink on mixed ph. 2 schizophrenia readout

7 news sources are covering this Business story right now — Newsylist is tracking how fast it spreads.